Butner, Joseph D.
Wang, Zhihui http://orcid.org/0000-0001-6262-700X
Elganainy, Dalia
Al Feghali, Karine A.
Plodinec, Marija
Calin, George A.
Dogra, Prashant
Nizzero, Sara
Ruiz-RamÃrez, Javier
Martin, Geoffrey V.
Tawbi, Hussein A. http://orcid.org/0000-0003-1942-851X
Chung, Caroline
Koay, Eugene J. http://orcid.org/0000-0001-7675-3461
Welsh, James W.
Hong, David S.
Cristini, Vittorio http://orcid.org/0000-0002-7909-4278
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1U01CA196403, 1U01CA213759, 1R01CA226537, 1R01CA222007, U54CA210181, 1R01CA222007, 1U01CA196403, U54CA210181, 1U01CA196403, 1U01CA213759, 1R01CA226537, 1R01CA222007, U54CA210181)
National Science Foundation (DMS-1930583, DMS-1930583)
Article History
Received: 28 August 2019
Accepted: 14 November 2020
First Online: 4 January 2021
Competing interests
: J.W.W. reports research support from GlaxoSmithKline, Bristol Myers Squibb, Merck, Nanobiotix, Mavupharma and Checkmate Pharmaceuticals. J.W.W. serves on the scientific advisory board for RefleXion Medical, MolecularMatch, OncoResponse, Checkmate, Mavupharmaceuticals and Alpine Immune Sciences. J.W.W. is co-founder of Healios Oncology, MolecularMatch and OncoResponse and serves as an advisor to AstraZeneca, Merck, MolecularMatch, Incyte, Aileron and Nanobiotix. J.W.W. has the following patents: MP470 (amuvatinib), MRX34 regulation of PD-L1, and the X-ray tomography technique to overcome immune resistance. The University of Texas MD Anderson Cancer Center has a trademark for RadScopal.